Medical Grand Rounds

*Presented by*

Yale School of Medicine, Department of Internal Medicine,

Section of Pulmonary, Critical Care & Sleep Medicine

The 7th Annual Jack A. Elias Advances in Biomedical Sciences Lectureship

Naftali Kaminski, MD

Boehringer Ingelheim Pharmaceuticals, Inc. Professor of Medicine (Pulmonary)

Section Chief, Pulmonary, Critical Care & Sleep Medicine

“The Road to #CureIPF”

**Date: September 17, 2020 Time: 8:30-9:30am**

**Location:** [**https://zoom.us/j/94896766303?pwd=UWFrcG9GNXMvcWZ3YU4ycUc5VEVSdz09**](https://zoom.us/j/94896766303?pwd=UWFrcG9GNXMvcWZ3YU4ycUc5VEVSdz09)

***There is no corporate support for this activity***

This course will fulfill the licensure requirement set forth by the State of Connecticut

**ACCREDITATION:**

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**TARGET AUDIENCE:**

**Attending physicians, house staff, fellows, medical students, PA’s**

**NEEDS ASSESSMENT:**

Idiopathic pulmonary fibrosis (IPF) is the most common form of interstitial lung disease and it is associated with high morbidity and mortality. Clinicians need to know about the diagnosis and management of IPF, and understand the molecular mechanisms underlying this disease.

**LEARNING OBJECTIVES:**

1. To provide an update of our current diagnosis and management of Idiopathic Pulmonary Fibrosis
2. 2. To describe the recent insights derived from applying high throughput ‘omics’ and systems biology technologies changed our understanding of IPF
3. 3. To describe how most recent insights from single cell profiling of human IPF lungs suggest that fibrosis may be reversible

**DESIGNATION STATEMENT**

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

**FACULTY DISCLOSURES:**

Course Director: Vincent Quagliarello, MD - None

Speaker: Naftali Kamniski, MD-

Biogen Idec, Boehringer Ingelheim, Third Rock, Samumed, NuMedii, Indaloo, Theravance, LifeMax, Three Lake Partners, RohBar, Pliant; Fees; Consultant

Pliant; Equity; Consultant

MiRagen; Reagents; Collaborator

Veracyte; Grant and Royalties; Collaborator and inventor

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.